Modality: In Situ Hybridization (ISH/RNAscope)

  • HistologiX

    HistologiX is a GLP- and GCP-compliant tissue-based CRO headquartered inside BioCity Nottingham. The laboratory supports discovery through to late-stage clinical studies with end-to-end histology, multiplex immunostaining and digital pathology services. Core workflows cover multiplex IHC on Leica and Ventana platforms, RNAscope and BaseScope assays, image analysis in HALO and Visiopharm, and project management backed by CLIA-equivalent quality systems.

    Specialist programmes include:
    • Immuno-oncology biomarker development, immune cell phenotyping and TME mapping in FFPE cohorts
    • Cross-reactivity, toxicology and clinical trial sample management with rapid GLP reporting
    • Integration of pathologist scoring, AI quantification and regulatory documentation for submission-ready packages

    HistologiX works with pharma, biotech and diagnostic developers who need UK-based capacity for high-plex imaging and robust data packages.

  • OracleBio

    OracleBio is a quantitative digital pathology contract research organisation based at BioCity Scotland. The team delivers image analysis that supports translational research, clinical trials and companion diagnostic programmes, working across multiplex immunofluorescence, multiplex IHC and RNAscope assays. Scientists routinely analyse whole-slide scans produced on Akoya, Leica and Philips platforms using HALO, Visiopharm and Definiens pipelines, generating regulatory-ready reports aligned with GCP quality management.

    Core strengths include:
    • Study design support for multiplex biomarker panels and tissue microarrays
    • Bespoke deep-learning segmentation, cell phenotyping and spatial statistics (TME, proximity, neighbourhood analysis)
    • Pathologist review and quality control integrated with project management workflows

    OracleBio partners with biopharma globally but keeps assay development and data science in Glasgow, enabling UK clients to access rapid turnaround support while meeting data residency requirements.